Metoprolol - IntelGenx

Drug Profile

Metoprolol - IntelGenx

Alternative Names: INT-0001; INT-0001/2004

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IntelGenx Corp.
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hypertension

Highest Development Phases

  • Suspended Heart failure; Hypertension

Most Recent Events

  • 30 Mar 2016 Suspended - Phase-II for Heart failure in Canada (PO)
  • 30 Mar 2016 Suspended - Phase-II for Hypertension in Canada (PO)
  • 23 Mar 2016 Metoprolol - IntelGenx is available for licensing as of 23 Mar 2016. http://www.intelgenx.com/partnering/default.aspx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top